Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
(World News Science)

Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome Smoking cessation is the third indication for AXS-05 Phase 2 trial initiation anticipated in the first quarter of 2018 NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, entered into a research collaboration with Duke University to evaluate AXS-05 in a Phase 2 clinical trial in smokers attempting to quit. AXS-05 is a novel, oral, fixed-dose combination of dextromethorphan and bupropion. This collaboration builds upon preclinical...